TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis

February 21, 2017, The Scripps Research Institute
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.

Relapsing multiple sclerosis is a form of the disease where patients experience a periodic worsening of symptoms. Sensory and motor loss of function leads to increased disability, and patients can need a cane or wheelchair. A signature of the disease is the appearance of lesions in the brain, which are linked to inflammation and can show up through MRI detection during active periods of multiple sclerosis relapse.

Ozanimod, discovered by TSRI Professors Hugh Rosen and Ed Roberts and their laboratories, acts as a sphingosine 1-phosphate 1 (S1PR1) receptor agonist—modulating S1PR1 signaling and blocking sources of inflammation. Rosen and Roberts went on to co-found Receptos, a clinical stage biopharmaceutical company that took ozanimod into Phase 1, 2 and 3 clinical trials and was then acquired by Celgene. Ozanimod is the first New Chemical Entity discovered from a starting point in the NIH Common Fund Molecular Libraries Initiative to reach and succeed in advanced clinical studies.

As reported by Celgene, results from the randomized, Phase 3, double-blind, double-dummy, active-controlled SUNBEAM study among 1,346 participants show that ozanimod met its primary endpoint in reducing annualized relapse rate (ARR) of relapsing , compared with an alternate drug treatment called weekly interferon (IFN) β-1a (Avonex).

Administered at doses of both 1 mg and 0.5 mg, ozanimod demonstrated statistically significant and clinically meaningful improvements, compared to Avonex, for the primary endpoint of ARR and the measured secondary endpoints of the number of MRI-detected lesions and the number of new or enlarging "T2" MRI lesions at after a year of treatment.

"It is exciting and rewarding to see the results of this new Phase 3 trial, which confirm the safety profile from the two-year extension data from the Phase 2 RADIANCE study and underscore ozanimod's efficacy in reducing the burden of MS symptoms on patients and their families," said Rosen. "We look forward to seeing the full study results, as well as the results from the Phase 3 study evaluating ozanimod in patients with ulcerative colitis."

Scientists involved in the trial plan to present the full Phase 3 trial results at an upcoming international scientific meeting.

Explore further: Study shows path to 'dial down' autoimmunity without compromising immune response

Related Stories

Study shows path to 'dial down' autoimmunity without compromising immune response

January 19, 2016
A new study led by scientists at The Scripps Research Institute (TSRI) shows how dangerous autoimmune responses, seen in diseases such as lupus and multiple sclerosis, might be "dialed down" without compromising the immune ...

Celgene will buy drug developer Receptos for $7.32 billion

July 14, 2015
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.

MS drug candidate also shows promise for ulcerative colitis

October 28, 2014
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI).

Study shows ozanimod as effective in treating ulcerative colitis

May 4, 2016
Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical ...

Study sheds light on the biology of progressive form of multiple sclerosis, suggests a new potential path for treatment

February 8, 2017
A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) ...

Genentech announces favorable results for MS drug ocrelizumab

October 9, 2015
Swiss pharmaceutical company Genentech a member of the Roche Group, has released (at the European Committee for Treatment and Research in Multiple Sclerosis meeting) findings from Phase III clinical trials for its multiple ...

Recommended for you

Brain response study upends thinking about why practice speeds up motor reaction times

August 16, 2018
Researchers in the Department of Physical Medicine and Rehabilitation at Johns Hopkins Medicine report that a computerized study of 36 healthy adult volunteers asked to repeat the same movement over and over became significantly ...

Newly identified role for inhibition in cerebellar plasticity and behavior

August 16, 2018
Almost everyone is familiar with the unique mixture of surprise and confusion that occurs after making a mistake during an everyday movement. It's a fairly startling experience—stumbling on a step or accidentally missing ...

Men and women show surprising differences in seeing motion

August 16, 2018
Researchers reporting in the journal Current Biology on August 16 have found an unexpected difference between men and women. On average, their studies show, men pick up on visual motion significantly faster than women do.

How people use, and lose, preexisting biases to make decisions

August 16, 2018
From love and politics to health and finances, humans can sometimes make decisions that appear irrational, or dictated by an existing bias or belief. But a new study from Columbia University neuroscientists uncovers a surprisingly ...

Working memory might be more flexible than previously thought

August 16, 2018
Breaking with the long-held idea that working memory has fixed limits, a new study by researchers at Uppsala University and New York University suggests that these limits adapt themselves to the task that one is performing. ...

Protein droplets keep neurons at the ready and immune system in balance

August 15, 2018
Inside cells, where DNA is packed tightly in the nucleus and rigid proteins keep intricate transport systems on track, some molecules have a simpler way of establishing order. They can self-organize, find one another in crowded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.